Artigo Acesso aberto Revisado por pares

Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?

2020; Springer Nature; Volume: 123; Issue: 5 Linguagem: Inglês

10.1038/s41416-020-0930-7

ISSN

1532-1827

Autores

Oliver Pickles, Lennard Y. W. Lee, Thomas Starkey, Luke Freeman-Mills, Anna Olsson‐Brown, Vinton W.T. Cheng, D.J. Hughes, Alvin Lee, Karin Purshouse, Gary Middleton,

Tópico(s)

Cancer Immunotherapy and Biomarkers

Resumo

Summary The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.

Referência(s)